Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program

PRESS RELEASE Research Findings

23/02/2021

Eli Lilly and Company

To discover more on this topic, please tap 'Read more'.

Related News

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509 15th floor South Sathorn road Yannawa Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us